Identification of novel autoantibody signatures and evaluation of a panel of autoantibodies in breast cancer

Cuipeng Qiu,Bofei Wang,Peng Wang,Xiao Wang,Yan Ma,Liping Dai,Jianxiang Shi,Keyan Wang,Guiying Sun,Hua Ye,Jianying Zhang
DOI: https://doi.org/10.1111/cas.15021
IF: 5.7
2021-07-04
Cancer Science
Abstract:<p>Tumor-associated autoantibodies (TAAbs) could be serological tumor markers. This study aims to discover novel TAAbs signature for breast cancer (BC) detection. The protein microarray was employed to identify candidate TAAbs which were further validated in 1,197 sera from BC, benign breast diseases (BD), and healthy controls (HC) by enzyme-linked immunosorbent assay. And 319 preoperative and postoperative sera were further evaluated. A panel was determined using four different classifiers. Twelve TAAbs were identified with frequencies of 15.8%-59.2%, their levels were significantly decreased in postoperative sera compared to those in preoperative sera (<i>p</i>&lt;0.05). A panel with 6 TAAbs was developed and validated. The area under the curves (AUCs) were 0.879 (74.3% sensitivity, 91.9% specificity) and 0.865 (69.7 % sensitivity, 91.7% specificity) for distinguishing BC from HC in the training set and test set, respectively. It had an AUC of 0.884 (71.2% sensitivity, 90.5% specificity) for discriminating BC from BD. For identifying BC from all controls (HC+BD), the AUC was 0.916 (78.9% sensitivity, 90.2% specificity). The AUCs of the panel were 0.920 and 0.934 for distinguishing stage I-II and age&lt;50 BC from HC, respectively. These identified TAAbs may have promising value in clinical applications serving as a non-invasive approach to improve BC detection.</p><p>Supporting information</p>
oncology
What problem does this paper attempt to address?